13FGuru
Sign in with Google Sign in with Discord

NYSE · Health Care

Pfizer PFE

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19.

Sources StockAnalysis company profile stockanalysis.com
Biotechnology: Pharmaceutical Preparations

Company profile

Business mix

  • It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
  • It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity.
  • In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers.
  • Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 2 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 19.87 FCF 6.39% Buyback -0.26%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Fairfax Financial Prem Watsa 1.4% $27.8M 2026-03-31
Kahn Brothers Group 2.4% $13.6M 2026-03-31

Recent trading changes over the last 4 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 3 Last 4 13F filing periods
Net reducers 1 Last 4 13F filing periods
Unchanged holders 1 Share count unchanged
Increase amount $45.2M Estimated from net added shares
Reduction amount $7.0M Estimated from net reduced shares
Net share change / base shares +85.3% +1,549,037 / 1,815,054
Fairfax Financial Prem Watsa 4 filing periods
13F 2025-06-30 Filed 2025-08-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-09-30 Filed 2025-11-14
Major increase Shares 36.9% 13F value change +$6.9M
13F 2025-12-31 Filed 2026-02-17
Unchanged Shares 0.0% 13F value change $0
13F 2026-03-31 Filed 2026-05-15
Minor increase Shares 11.2% 13F value change +$5.6M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 650,900 Last 4 periods +340,000 (+52.2%) Total shares 990,900 Value $27.8M
Kahn Brothers Group 4 filing periods
13F 2025-06-30 Filed 2025-08-14
Minor reduction Shares -0.6% 13F value change -$910,836
13F 2025-09-30 Filed 2025-11-12
Minor reduction Shares -3.3% 13F value change +$298,856
13F 2025-12-31 Filed 2026-02-12
Major reduction Shares -21.7% 13F value change -$4.2M
13F 2026-03-31 Filed 2026-05-08
Minor reduction Shares -12.5% 13F value change -$182,053
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 735,189 Last 4 periods -250,456 (-34.1%) Total shares 484,733 Value $13.6M
Gotham Asset Management Joel Greenblatt 3 filing periods
13F 2025-06-30 Filed 2025-08-14
Major increase Shares 110.8% 13F value change +$11.0M
13F 2025-09-30 Filed 2025-11-14
Major increase Shares 62.8% 13F value change +$15.6M
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -40.5% 13F value change -$15.7M
Settlement As of 13F 2025-12-31 · Filed 2026-02-17
Base shares 428,965 Last 4 periods +446,739 (+104.1%) Total shares 875,704 Value $21.8M
Starboard Value Jeff Smith 3 filing periods
13F 2025-03-31 Filed 2025-05-15
New Shares - 13F value change +$195.9M
13F 2025-06-30 Filed 2025-08-14
Minor increase Shares 10.5% 13F value change +$11.2M
13F 2025-09-30 Filed 2025-11-14
Sold out Shares -100.0% 13F value change -$207.1M
Settlement As of 13F 2025-09-30 · Filed 2025-11-14
Base shares 0 Last 4 periods +0 (New) Total shares 0 Value $0
Bridgewater Associates Ray Dalio 2 filing periods
13F 2025-03-31 Filed 2025-05-14
New Shares - 13F value change +$41.9M
13F 2025-06-30 Filed 2025-08-13
Major reduction Shares -38.8% 13F value change -$17.4M
Settlement As of 13F 2025-06-30 · Filed 2025-08-13
Base shares 0 Last 4 periods +1,012,754 (New) Total shares 1,012,754 Value $24.5M

Recent mentions

No public mentions.